Hi, I was hoping that you could disseminate this info on a Phase III prostate
vaccine trial. People are needed for the on-going confirmatory trial:


Seattle, WA (January 12, 2004) - Dendreon Corporation (NASDAQ:DNDN) today
announced updated survival data from patients with advanced prostate cancer with
Gleason Scores of seven and less who participated in its completed and
previously reported Phase 3 trial (D9901) of Provenge, the Company's
investigational immunotherapy for the treatment of prostate cancer.

Patients with Gleason Scores of seven and less receiving Provenge had a
significant survival advantage, having on average an 89 percent overall increase
in their survival time as compared to placebo (log rank p= 0.047, hazard ratio =
1.89). This benefit is reflected by a prolongation in the median survival time
in patients receiving Provenge by 8.4 months (30.7 months versus 22.3 months).
At 30 months from randomization, the survival rate for Provenge-treated patients
is 3.7 times higher than for patients receiving placebo (53 percent versus 14
percent, p= 0.001).

Full Article:
http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=126255&Header=IR



[input] The BEST PIN-FREE International Calling Cards on the Market!
http://callingtheworld.pushline.com






---------------------------------
Do you Yahoo!?
Friends. Fun. Try the all-new Yahoo! Messenger

[Non-text portions of this message have been removed]